# Swedish Orphan Biovitrum clinical trials: 82 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 82 trials with Swedish Orphan Biovitrum as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Swedish Orphan Biovitrum: 82 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/swedish-orphan-biovitrum

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 82
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 82, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07909005 | Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant. | Swedish Orphan Biovitrum | Observational | Not yet recruiting | Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909005) |
| October 27, 2026 | NCT07898774 | A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant... | Swedish Orphan Biovitrum | Phase 3 | Recruiting | C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898774) |
| August 26, 2026 | NCT07786922 | A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard... | Swedish Orphan Biovitrum | Phase 2/3 | Not yet recruiting | Aplastic Anemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786922) |
| August 19, 2026 | NCT07774455 | Pacritinib Effectiveness in Real-world Settings | Swedish Orphan Biovitrum | Observational | Recruiting | Myelofibrosis (MF) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774455) |
| August 5, 2026 | NCT07746895 | Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study | Swedish Orphan Biovitrum | Phase 4 | Recruiting | C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746895) |
| July 16, 2026 | NCT07706868 | An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and... | Swedish Orphan Biovitrum | Phase 4 | Withdrawn | Systemic Juvenile Idiopathic Arthritis (sJIA), Adult Onset Still's Disease (AOSD) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706868) |
| May 28, 2025 | NCT06992505 | Assessment of Macrophage Activation syndromE in STill's Disease in Italy | Swedish Orphan Biovitrum | Observational | Completed | Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset, Still's Disease, Adult-Onset | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06992505) |
| April 23, 2025 | NCT06940830 | Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa | Swedish Orphan Biovitrum | Phase 4 | Active not recruiting | Hemophilia A | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06940830) |
| January 17, 2025 | NCT06782373 | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Swedish Orphan Biovitrum | Phase 2 | Recruiting | VEXAS, VEXAS Syndrome | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06782373) |
| December 31, 2024 | NCT06752850 | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | Swedish Orphan Biovitrum | Phase 4 | Active not recruiting | Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia, Classic Hemophilia, Synovial... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752850) |
| December 4, 2024 | NCT06716814 | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | Swedish Orphan Biovitrum | Phase 3 | Active not recruiting | Haemophilia A (Moderate or Severe) | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06716814) |
| October 30, 2024 | NCT06666335 | A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF | Swedish Orphan Biovitrum | Phase 4 | Withdrawn | Familial Mediterranean Fever (FMF ) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06666335) |
| August 30, 2024 | NCT06579144 | Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A | Swedish Orphan Biovitrum | Phase 1 | Completed | Hemophilia A | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06579144) |
| May 8, 2024 | NCT06405152 | Assessment of Macrophage Activation syndromE in STill's Disease | Swedish Orphan Biovitrum | Observational | Completed | Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06405152) |
| January 26, 2024 | NCT06227429 | A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients | Swedish Orphan Biovitrum | Observational | Withdrawn | Hereditary Tyrosinemia, Type I | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06227429) |
| September 21, 2023 | NCT06047210 | Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis | Swedish Orphan Biovitrum | Observational | Completed | Hemophagocytic Lymphohistiocytoses | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06047210) |
| May 12, 2023 | NCT05856266 | An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or... | Swedish Orphan Biovitrum | Phase 4 | Terminated | Hemophilia A, Hemophilia B | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05856266) |
| April 18, 2023 | NCT05817812 | A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa | Swedish Orphan Biovitrum | Phase 3 | Completed | Hemophilia A, Severe | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05817812) |
| April 14, 2023 | NCT05814159 | A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD) | Swedish Orphan Biovitrum | Phase 3 | Active not recruiting | Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814159) |
| March 20, 2023 | NCT05776472 | A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Swedish Orphan Biovitrum | Observational | Active not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05776472) |
| February 24, 2023 | NCT05744063 | A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese... | Swedish Orphan Biovitrum | Phase 4 | Completed | Primary Hemophagocytic Lymphohistiocytosis | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05744063) |
| December 8, 2021 | NCT05148299 | A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation | Swedish Orphan Biovitrum | Phase 2 | Completed | Transplant-Associated Thrombotic Microangiopathy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05148299) |
| October 27, 2021 | NCT05096403 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) | Swedish Orphan Biovitrum | Phase 3 | Completed | Cold Agglutinin Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05096403) |
| August 12, 2021 | NCT05001737 | Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | Swedish Orphan Biovitrum | Phase 3 | Completed | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus... | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05001737) |
| June 29, 2021 | NCT04943042 | An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP | Swedish Orphan Biovitrum | Observational | Completed | Immune Thrombocytopenia, ITP | 199 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04943042) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 4 |
| Phase 2 | 11 |
| Phase 2/3 | 5 |
| Phase 3 | 16 |
| Phase 4 | 9 |
| Not applicable | 1 |
| Observational | 23 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 58 |
| Terminated | 8 |
| Active not recruiting | 6 |
| Withdrawn | 4 |
| Recruiting | 4 |
| Not yet recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemophilia A | 14 |
| Blood Coagulation Disorders | 10 |
| Coagulation Protein Disorders | 10 |
| Arthritis, Juvenile | 9 |
| Lymphohistiocytosis, Hemophagocytic | 9 |
| Hemophilia B | 7 |
| Stomatitis | 7 |
| Still's Disease, Adult-Onset | 6 |
| Hemorrhagic Disorders | 6 |
| Hematologic Diseases | 5 |
| Genetic Diseases, Inborn | 5 |
| Macrophage Activation Syndrome | 5 |
| Neoplasms | 4 |
| Tyrosinemias | 4 |
| Mucositis | 3 |
| Head and Neck Neoplasms | 3 |
| Leukemia | 3 |
| Rare Diseases | 3 |
| Lymphoma, Follicular | 2 |
| Multiple Myeloma | 2 |
| Hematologic Neoplasms | 2 |
| Lymphoma | 2 |
| Primary Myelofibrosis | 2 |
| Mucopolysaccharidosis III | 2 |
| Anemia, Hemolytic, Autoimmune | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B background check companies in the United States](https://specstream.ai/data/businesses/b2b-background-check-companies/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
- [Metal plating companies in the United States](https://specstream.ai/data/businesses/metal-plating-companies/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
